Novo Nordisk and bluebird bio Enter 3-Year Gene Therapy Collaboration
Updated: Jul 22
Cambridge, Massachusetts-based bluebird bio and Bagsvaerd, Denmark-based Novo Nordisk announced they have agreed to collaborate to develop next-generation genome editing therapies for genetic diseases, including hemophilia. The deal will last three years, with a top priority to develop a gene therapy for Hemophilia A.
We will keep the community informed if there are any more developments on this partnership.